Search Results
Surviving Chemo: A Little Planning Goes a Long Way
Just the thought of chemotherapy can be enough to make one feel sick. Toxic drugs powerful enough to kill or damage cancer cells also take their toll on healthy cells. While everyone tends to respond differently, most agree the treatments come with unpleasant side effects.
Check out these 14 tips from The Leukemia & Lymphoma Society that should help make the experience a little less uncomfortable:
Working with Lawmakers to Address the Unique Needs of Cancer Patients
As the coronavirus continues its spread, The Leukemia & Lymphoma Society (LLS) has a vital role to play in ensuring our government takes every step necessary to protect cancer patients. With that in mind, we’re sharing with our community what LLS has been doing to make sure the unique needs of blood cancer patients are being heard by the government at this unprecedented time.
Another Advance for AML
The steady pace of progress in treating patients with acute myeloid leukemia (AML), still one of the most deadly blood cancers, continued with today’s U.S. Food & Drug Administration’s second approval of a drug called ivosidenib (Tibsovo) that works for patients with a specific subtype of AML.
Five Reasons to Give Thanks
The Leukemia & Lymphoma Society (LLS) exists to find cures for blood cancers and improve the quality of life of patients and their families. The fervor with which experts, patients and supporters rally around this cause is impressive and it’s only because of that synergy that we’re able to make such significant progress in saving lives.
In the spirit of Thanksgiving, we wanted to share five reasons we are giving thanks this holiday season.
Fludarabine
Fludarabine is FDA approved to treat people who have chronic lymphocytic leukemia (CLL) who have not responded to at least one standard alkylting-agent-containing regimen or whose disease has progressed during treatment with such a regimen. This medicine may rarely cause a temporary loss of hair. After treatment with fludarabine has ended, normal hair growth should return.
Lenalidomide
Lenalidomide is FDA approved to treat patients with:
Researchers Share Key Career Advice with LLS College Club Members
I recently had the privilege of moderating an LLS on Campus Researcher Panel attended by LLS college club members from nearly 30 universities across the country. These clubs bring together students interested in pursuing health-related careers and provide opportunities to hear from scientists working to better understand and treat blood cancers.
Helping Blood Cancer Patients and Families When It's Needed Most
In honor of Blood Cancer Awareness Month, Dr. Gwen Nichols reflects on our vital work to support blood cancer patients and their families.
3 Things You Might Like to Know About Being Newly Diagnosed
A cancer diagnosis is a pivotal moment in a person’s lifetime.
From that point forward, it’s a part of who you are. It shapes how you think about the world—through the lens of your diagnosis and what’s important to you.
Ivosidenib
Ivosidenib is FDA approved for the treatment of patients with a susceptible IDH1 mutation as detected by an FDA-approved test in:
Rituximab and hyaluronidase human
Rituximab and hyaluronidase human is a combination of rituximab, a CD20-directed cytolytic antibody, and hyaluronidase human, an endoglycosidase, indicated for the treatment of adult patients with:
Announcing a New Light The Night T-shirt Contest Winner, Drumroll Please…
The Leukemia & Lymphoma Society (LLS) has officially tallied up the votes for the 2016 Light The Night t-shirt contest submissions, and the winning design comes from 37-year-old Joshua Redmond of Centerville, Ohio.
A graduate of Ohio University’s School of Fine Art, Redmond earned his degree in graphic design and printmaking and has been working professionally in the industry for over a decade.
The Gift of Time: Giving More Moments to Blood Cancer Patients
As we transition from one year to the next, we often reflect on milestones achieved, challenges faced, and moments shared with those we love. It’s a time to focus on what’s most important—family, community, and how we’ll spend our time going forward. At the Leukemia & Lymphoma Society (LLS), we know that time is more than just a passing moment for blood cancer patients. It’s the most valuable gift they can receive.
Meet the Researcher: Maria Figueroa, MD
Our “Meet the Researcher” series on The LLS Blog shares what our outstanding LLS-funded researchers are working on, the incredible impact they’re making in the fight against blood cancer, and what inspires their efforts to find better treatments and cures. Dr. Maria “Ken” Figueroa, Associate Professor and Co-Leader of the Cancer Epigenetics Research Program at Sylvester Comprehensive Cancer Center, part of the University of Miami Health System, is focused on an exciting area of research called epigenetics.
LLS “FACEBOOK LIVE” INSPIRES THE NEXT GENERATION OF SCIENTISTS
As schools and education communities across the country have had to adjust to a new way of learning online, The Leukemia & Lymphoma Society’s Pennies for Patients program (www.penniesforpatients.org), a science-based service-learning program for schools, has shifted in-person school learning events to a virtual semi-weekly STEM+ curriculum program to inspire the next generation of scientists and doctors.